In March 2009, the Chinese government laid out its ambitious RMB850 billion (USD125 billion) healthcare reform plan. This reform will reshape the landscape for China’s pharmaceutical and healthcare industries over the next decade. Whether you are already operating in China or are looking to enter the Chinese market, it is important to understand the road ahead.
At Baker & McKenzie, we have the knowledge and experience to help you navigate the complex maze of rules and regulations, identify opportunities and challenges, and manage risks. We have been doing business in China and Hong Kong for nearly 40 years, advising an extensive list of pharmaceuticals, medical devices, healthcare products, manufacturers and distributors, medical and research institutions, clinical research organizations, as well as health and regulatory authorities on M&A. We have experience in alliance and joint venture transactions and a broad spectrum of regulatory and compliance issues.
For global players operating in the region or Asian companies or suppliers involved in the industry, our lawyers provide the legal and business solutions required for strategic and operational success in the Greater China region.
Learn more about how we can help you.
Awards and Recognition
- China Deal of the Year: Sinopharm Group HKD10 billion (USD1.3 billion) IPO, Asiamoney 2009
- Highly Recommended Law Firm for Life Sciences: Corporate & Commercial (Hong Kong / China), PLC Which Lawyer? 2007-2009, 2011